Below are the most recent publications written about "Receptors, Metabotropic Glutamate" by people in Profiles.
-
Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018 01 16; 9(1):4.
-
Friedman LK, Sharma A, Corcia M, Webster T, Qazi L, Simsovits D, Khalil Y, Hu S, Kantrowitz M, Hong H. Selective inhibition of metabotropic glutamate type 1 alpha receptor (mGluR1a) reduces cell proliferation and migration following status epilepticus in early development. Int J Dev Neurosci. 2016 Nov; 54:6-21.
-
Lakkaraju SK, Yu W, Raman EP, Hershfeld AV, Fang L, Deshpande DA, MacKerell AD. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors. J Chem Inf Model. 2015 Mar 23; 55(3):700-8.
-
Teh JL, Shah R, Shin SS, Wen Y, Mehnert JM, Goydos J, Chen S. Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. Pigment Cell Melanoma Res. 2014 Jul; 27(4):621-9.
-
Teh JL, Chen S. Glutamatergic signaling in cellular transformation. Pigment Cell Melanoma Res. 2012 May; 25(3):331-42.
-
Eisenman LM. Ethanol and vestibular stimulation reveal simple and complex aspects of cerebellar heterogeneity. Cerebellum. 2011 Sep; 10(3):475-83.
-
McBride SM, Choi CH, Schoenfeld BP, Bell AJ, Liebelt DA, Ferreiro D, Choi RJ, Hinchey P, Kollaros M, Terlizzi AM, Ferrick NJ, Koenigsberg E, Rudominer RL, Sumida A, Chiorean S, Siwicki KK, Nguyen HT, Fortini ME, McDonald TV, Jongens TA. Pharmacological and genetic reversal of age-dependent cognitive deficits attributable to decreased presenilin function. J Neurosci. 2010 Jul 14; 30(28):9510-22.
-
Gong Y, Lippa CF, Zhu J, Lin Q, Rosso AL. Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain Res. 2009 Oct 06; 1292:191-8.
-
Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec; 327(3):827-39.
-
Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004 May; 89(4):876-85.